SCHEMBL530293

SCHEMBL530293

O=c1cc(-c2cccc3ccccc23)oc2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.67
NPC1 O15118 4/20 0.67
RAB9A P51151 3/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
AKR1C3 P42330 1/20 0.67
AKR1C2 P52895 1/20 0.67
AKR1C1 Q04828 1/20 0.67
CYP3A4 P08684 5/20 0.66
TP53 P04637 4/20 0.66
MEN1 O00255 4/20 0.66
CYP2C9 P11712 4/20 0.66
CYP2C19 P33261 4/20 0.66
KMT2A Q03164 4/20 0.66
CYP2D6 P10635 3/20 0.66
MAPT P10636 3/20 0.66
KDM4E B2RXH2 2/20 0.66
ALOX15 P16050 2/20 0.66
ALOX12 P18054 1/20 0.66
RECQL P46063 1/20 0.66
HSD17B10 Q99714 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31061270 1.00 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL17786570 0.85 EGFR (0.58) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL25186939 0.83 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL1974743 0.83 HPGD (0.61) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL30956969 0.82 MAOB (0.62) HPGDNPC1RAB9ACYP3A4TP53
SCHEMBL5468830 0.82 MAOB (0.62) HPGDNPC1RAB9ACYP3A4TP53
SCHEMBL4634256 0.81 HPGD (0.73) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL9080220 0.81 AKR1C3 (0.72) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL87773 0.80 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3
SCHEMBL1423180 0.80 HPGD (0.67) HPGDNPC1RAB9ASMN1; SMN2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11596657-B2 Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2023-03-07 US claimed
US-20220143143-A1 USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES UNIV MCMASTER (CA) 2022-05-12 US claimed
EP-3920908-A1 USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES McMaster University (CA) 2021-12-15 EP claimed
WO-2020160680-A1 USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES. MCMASTER UNIVERSITY (CA) 2020-08-13 WO claimed
US-10736927-B2 Pharmaceutical compositions for preventing or treating inflammatory bowel diseases INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE) (FR) 2020-08-11 US claimed
US-20190282638-A1 USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) 2019-09-19 US claimed
EP-3522902-A1 USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS Institut National de la Recherche Agronomique (FR) 2019-08-14 EP claimed
US-20180250350-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) 2018-09-06 US claimed
EP-3337492-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-06-27 EP claimed
WO-2018065132-A1 USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS. INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2018-04-12 WO claimed
EP-3167892-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING IMFLAMMATORY BOWEL DISEASES INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-05-17 EP claimed
US-20170121678-A1 METHODS AND COMPOSITIONS TO STABILIZE DIFFERENT STEM CELL STATES UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2017-05-04 US claimed
WO-2017032739-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-03-02 WO claimed
CN-104471391-B Differentiate that there is the method for the part of the AHR receptor of therapeutic sebum suppression activity and described part 赛斯安制药公司 2016-12-07 CN claimed
WO-2015187689-A1 METHODS AND COMPOSITIONS TO STABILIZE DIFFERENT STEM CELL STATES UNIVERSITY OF WASHINGTON - CENTER FOR COMMERCIALIZATION (US) 2015-12-10 WO claimed
EP-2850429-A1 METHOD FOR IDENTIFYING LIGANDS OF THE AHR RECEPTOR HAVING THERAPEUTIC SEBOSUPPRESSIVE ACTIVITY, AND SAID LIGANDS Thesan Pharmaceuticals, Inc. (US) 2015-03-25 EP claimed
CN-104471391-A Method for identifying ligands of the AHR receptor having therapeutic sebosuppressive activity, and said ligands SAURAT JEAN HILAIRE 2015-03-25 CN claimed
WO-2013171696-A1 METHOD FOR IDENTIFYING LIGANDS OF THE AHR RECEPTOR HAVING THERAPEUTIC SEBOSUPPRESSIVE ACTIVITY, AND SAID LIGANDS SAURAT JEAN HILAIRE (CH) 2013-11-21 WO claimed
CN-111867634-B Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers 阿尔吉法玛公司 2024-06-11 CN disclosed
EP-0062237-A1 Process for the determination of the carcinogenicity of chemical or physical agents YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) 1982-10-13 EP disclosed